SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for...
The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.15%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +1.38%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.22%. June E-mini S&P...
SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for...
The S&P 500 Index ($SPX ) (SPY ) today is up +2.10%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +2.30%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.19%. June E-mini S&P futures (ESM26...
The S&P 500 Index ($SPX ) (SPY ) today is up +1.73%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.97%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.79%. June E-mini S&P futures (ESM26...
APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including: - 75% and 85% patients maintained EASI-75 - 86% and 78% patients...
SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class...
Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway: - APEX Phase 2 Part A 52-week data expected this month - APEX Phase 2 Part...
SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th...
SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim...